Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
David Qualls(Memorial Sloan Kettering Cancer Center), Gilles Salles(Memorial Sloan Kettering Cancer Center), Paolo F. Caimi(University Hospitals Seidman Cancer Center), Kami J. Maddocks(The Ohio State University), Priyanka Pullarkat(Massachusetts General Hospital), Richard Godby(Mayo Clinic), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Venkatraman Seshan(Memorial Sloan Kettering Cancer Center), Connie Lee Batlevi(Memorial Sloan Kettering Cancer Center), Michael J. Buege(Memorial Sloan Kettering Cancer Center), Mwanasha H. Merrill(Dana-Farber Cancer Institute), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Michelle Okwali(Memorial Sloan Kettering Cancer Center), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), Brad S. Kahl(UW Health University Hospital), Jason T. Romancik(Emory University), Arushi Khurana(Mayo Clinic in Arizona), Graham T. Wehmeyer(Cornell University), Behzad Amoozgar(Washington University in St. Louis), Jennifer L. Crombie(Dana-Farber Cancer Institute), Sarah C. Rutherford(NewYork–Presbyterian Hospital), Jeremy S. Abramson(Massachusetts General Hospital), Nicholas Lambert(Baylor College of Medicine), Lori A. Leslie(Hackensack University Medical Center)
Cited by 47
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782